Literature DB >> 28451912

A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer.

Claudia Rutherford1, Daniel S J Costa2,3, Madeleine T King4,3, David P Smith5,6,7, Manish I Patel8.   

Abstract

PURPOSE: Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can be life-long. In this context, health-related quality of life (HRQOL) is important to patients and managing clinicians, and integral to treatment recommendations for NMIBC. The aim of this study was to develop a conceptual framework of patient-reported NMIBC symptoms, treatment side effects, and HRQOL impacts from three sources: (1) literature, (2) patients and (3) treating clinicians.
METHODS: First, we undertook a scoping literature review for studies reporting patient-reported outcomes associated with NMIBC. Outcomes were extracted and grouped conceptually. Then, we conducted semi-structured interviews with patients with NMIBC and treating clinicians. Patients were asked about symptoms and HRQOL impacts experienced from their NMIBC and treatments. Clinicians were asked about commonly reported outcomes, and outcomes they felt were important to assess clinically. Interviews were audio recorded, transcribed and content analysed.
RESULTS: A total of 125 symptom- and functioning-related expressions from 18 studies, 26 patients and 20 clinicians were coded into three themes and 18 sub-themes. Patients commonly reported blood in urine and frequent urination. Clinicians considered BCG sepsis and flu-like symptoms important outcomes to assess during treatment for NMIBC.
CONCLUSION: Our empirically derived conceptual framework identifies patient-reported outcomes that are important to people with NMIBC, provides the basis for the development of a new NMIBC-specific symptom index, and guides the design of a comprehensive PRO assessment plan for clinical practice in NMIBC and future clinical trials of treatments for NMIBC.

Entities:  

Keywords:  Early bladder cancer; Non-muscle invasive bladder cancer; Patient-reported outcomes; Quality of life; Symptom burden; Treatment symptoms

Mesh:

Substances:

Year:  2017        PMID: 28451912     DOI: 10.1007/s00520-017-3717-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  16 in total

1.  What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?

Authors:  A R Zlotta; J P van Vooren; K Huygen; A Drowart; M Decock; M Pirson; F Jurion; K Palfliet; O Denis; J Simon; C C Schulman
Journal:  Eur Urol       Date:  2000-04       Impact factor: 20.096

Review 2.  Synthesising qualitative and quantitative evidence: a review of possible methods.

Authors:  Mary Dixon-Woods; Shona Agarwal; David Jones; Bridget Young; Alex Sutton
Journal:  J Health Serv Res Policy       Date:  2005-01

Review 3.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course.

Authors:  N M Heney
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

4.  A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia.

Authors:  Rajkumar Cheluvappa; David P Smith; Sabina Cerimagic; Manish I Patel
Journal:  Int Urol Nephrol       Date:  2014-02-01       Impact factor: 2.370

Review 5.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.

Authors:  Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2011-03-22       Impact factor: 20.096

6.  Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  D Osoba; B Zee; J Pater; D Warr; J Latreille; L Kaizer
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 7.  Symptom burden: multiple symptoms and their impact as patient-reported outcomes.

Authors:  Charles S Cleeland
Journal:  J Natl Cancer Inst Monogr       Date:  2007

8.  Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial.

Authors:  Galina Velikova; Laura Booth; Adam B Smith; Paul M Brown; Pamela Lynch; Julia M Brown; Peter J Selby
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

Review 9.  Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report.

Authors:  Margaret Rothman; Laurie Burke; Pennifer Erickson; Nancy Kline Leidy; Donald L Patrick; Charles D Petrie
Journal:  Value Health       Date:  2009-09-25       Impact factor: 5.725

10.  Methods for the thematic synthesis of qualitative research in systematic reviews.

Authors:  James Thomas; Angela Harden
Journal:  BMC Med Res Methodol       Date:  2008-07-10       Impact factor: 4.615

View more
  8 in total

Review 1.  Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers.

Authors:  Risa L Wong; Alicia K Morgans
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

2.  Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review.

Authors:  Claudia Rutherford; Manish I Patel; Margaret-Ann Tait; David P Smith; Daniel S J Costa; Shomik Sengupta; Madeleine T King
Journal:  Qual Life Res       Date:  2020-09-22       Impact factor: 4.147

3.  Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study.

Authors:  Ahrang Jung; Matthew E Nielsen; Jamie L Crandell; Mary H Palmer; Sophia K Smith; Ashley Leak Bryant; Deborah K Mayer
Journal:  BJU Int       Date:  2019-09-25       Impact factor: 5.588

4.  Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer.

Authors:  Tullika Garg; Jill Nault Connors; Ilene G Ladd; Tyler L Bogaczyk; Sharon L Larson
Journal:  Bladder Cancer       Date:  2018-01-20

5.  Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review.

Authors:  Mieke Van Hemelrijck; Francesco Sparano; Debra Josephs; Mirjam Sprangers; Francesco Cottone; Fabio Efficace
Journal:  BMC Urol       Date:  2019-09-14       Impact factor: 2.264

6.  How Do We Meet the Supportive Care and Information Needs of Those Living With and Beyond Bladder Cancer?

Authors:  Sara Jane MacLennan; Steven MacLennan
Journal:  Front Oncol       Date:  2020-04-08       Impact factor: 6.244

7.  Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol.

Authors:  Claudia Rutherford; Madeleine T King; David P Smith; Daniel Sj Costa; Margaret-Ann Tait; Manish I Patel
Journal:  JMIR Res Protoc       Date:  2017-11-08

8.  Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist.

Authors:  Samantha J Mason; James W F Catto; Amy Downing; Sarah E Bottomley; Adam W Glaser; Penny Wright
Journal:  BJU Int       Date:  2018-06-08       Impact factor: 5.588

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.